跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/CTRI/2024/05/067983
CTRI/2024/05/067983尚未招募3 期

A Phase III, Randomized, Open-label, Multi Center, Global Study of Volrustomig MEDI5752 as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma, Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy - eVOLVE HNSCC

AstraZeneca AB0 个研究点目标入组 0 人开始时间: 待定最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

试验速览

阶段
3 期
状态
尚未招募
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • •Inclusion criteria
  • •Screening Part I
  • •In order to allow for pre-cCRT tumor sample collection, Part I Screening procedures may begin before cCRT is initiated.
  • •1. Participant must be 18 years of age, at the time of signing the ICF.
  • •2. Histologically or cytologically documented LA squamous cell carcinoma of the OP, HP, OC, or LX with no evidence of M0.
  • •3. Confirmed unresected Stage III HPV-mediated OPC, ie, T 0-3 N3 M0, or T4 N 0-3 M0; confirmed Stage IVA, IVB HPV-negative OPC/non-OPC, ie, T 1-3 N2 M0, or T4a-b any N, M0 or any T, N3, M0 or select Stage III ie, T3N1 according to the eighth edition of the AJCC staging manual TNM staging system.
  • •4. Confirmation of acceptable FFPE tumor tissue sample to assess PD-L1 expression. Samples must be acquired less than 3 months prior to first dose of cCRT. If such a sample is not available, a fresh tumor biopsy is required.
  • •5. For participants with OPC only: documented HPV status by IHC analysis with CINtec® Histology p16 Assay. If not available, a tumor tissue sample should be collected for testing at the central laboratory.
  • •6. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the Screening Part I ICF and Screening Part II ICF. Provision of signed and dated written Screening Part I ICF prior to any mandatory study-specific procedures and analyses is required. Before entering Screening Part II, a separate signed and dated written ICF is required. Participants may enter Screening Part II even if the results of the Screening Part I procedures are still pending. If investigators have confirmation of tumor tissue sample availability per tissue sample requirements in Inclusion Criteria 4 and 5, Screening Part I and II ICFs may be signed at the same visit.
  • •Screening Part II
  • •Participants may enter Screening Part II even if the results of the Screening Part I procedures are still pending. Participants are eligible to be randomized to the study only if all of the following Screening Part II inclusion criteria and none of the exclusion criteria apply:
  • •Type of Participant and Disease Characteristics
  • •7. Participants will have completed standard-of-care definitive cCRT with curative intent within 12 weeks 84 days prior to randomization as presented below. If baseline CT, MRI images are equivocal and or residual disease is suspected, investigators are strongly recommended to perform an FDG, PET assessment to confirm absence of progression. Where FDG, PET, avid lesions are detected and accessible, an endoscopy is recommended to be performed and a biopsy taken as clinically indicated to confirm residual disease and evaluate whether participation in this study is appropriate.
  • •a. If cisplatin-based systemic anticancer treatment was administered, participants will have received a cumulative cisplatin dose of 200 mg m2 overall. For example:
  • •High-dose cisplatin for 3 cycles plus concomitant RT
  • •Weekly cisplatin for 6 to 7 cycles plus concomitant RT.
  • •b. If non-cisplatin-based systemic anticancer treatment was administered, participants will have received either:
  • •Carboplatin combined with 5-FU for 3 cycles, plus concomitant RT
  • •Carboplatin combined with paclitaxel for 6 to 7

排除标准

  • •Exclusion criteria
  • •Exclusion Criteria should be assessed at Screening Part II only. Participants are excluded from the study if any of the following criteria apply
  • •Medical Conditions
  • •1.Histologically, cytologically confirmed head and neck cancer of any other primary
  • •anatomic location in the head and neck not specified in the Inclusion Criteria including participants with squamous cell carcinoma of unknown primary or non-squamous histologies eg, nasopharynx or salivary gland. Participants with 1 primary tumors are not eligible for the study.
  • •2.Participants with any of the following:
  • •a.Residual disease that needs further treatment with curative intent eg, salvage surgery, neck dissection, and RT after definitive cCRT administration per investigators’ assessment and institutional clinical practice;
  • •b. LA-HNSCC that was resected before definitive cCRT
  • •c. LA-HNSCC that was treated and is recurrent at the time of screening.
  • •3.Participants who have received RT alone as definitive local therapy for LA HNSCC.
  • •4.History of another primary malignancy except for
  • •a. T1N0M0 or T2N0M0 HNSCC resected 2 years before the first dose of study intervention with no RT or CTx.
  • •b. Malignancy treated with curative intent with no known active disease 2 years before the first dose of study intervention and of low potential risk for recurrence.
  • •c. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
  • •d. Adequately treated carcinoma in situ without evidence of disease.
  • •e. Cancer participant with incidental histologic findings of prostate cancer that,in the opinion of the investigator, is not deemed to require active therapy eg, incidentalprostate cancer identified following cystoprostatectomy that is TNM Stage pT2N0 may be enrolled.
  • •5. Unresolved toxicities caused by previous anticancer therapy, defined as toxicities other than alopecia and vitiligo not yet resolved to NCI CTCAE Version 5.0 Grade 1 or baseline. Participants with an irreversible toxicity that is not reasonably expected to be exacerbated by study intervention in the opinion of the investigator may be included.eg, hearing loss.
  • •6. As judged by the investigator, any condition that would interfere with evaluation of the study intervention or interpretation of participant safety or study results.
  • •7.Evidence of the following infections:
  • •a.Active infection including TB clinical evaluation that includes clinical history, physical examination, and radiographic findings and TB testing in line with local standard clinical practice.
  • •b. Uncontrolled HIV infection, the following criteria are required to define well-controlled HIV infection.
  • •Undetectable viral RNA load for 6 months,
  • •Cluster of differentiation 4 count of 500 cells µL, stable for at least 6 months on the same anti-HIV medications, and
  • •No history of AIDS (defined by either CD4 T cell count 200 cells µL and or AIDS-defining opportunistic infection.
  • •c Active or uncontrolled HBV or HCV. Participants are eligible if they:
  • •Have controlled HCV viral load defined as undetectable HCV RNA by polymerase chain reaction either spontaneously or in response to a successful prior course of anti-HCV therapy.

研究者

相似试验

进行中（未招募）
1 期
Study to compare the blood levels and safety of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency DiseasesPrimary immunodeficiency diseasesMedDRA version: 17.0Level: PTClassification code 10064859Term: Primary immunodeficiency syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disorders
EUCTR2013-002290-21-HUBio Products Laboratory Limited48
进行中（未招募）
1 期
Study to compare the blood levels and safety of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency DiseasesPrimary immunodeficiency diseasesMedDRA version: 17.1Level: PTClassification code 10064859Term: Primary immunodeficiency syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disorders
EUCTR2013-002290-21-GBBio Products Laboratory Limited48
进行中（未招募）
1 期
Study of First Line MEDI4736 with or without Tremelimumab Versus standard of care chemotherapy in Recurrent or Metastatic Head and Neck cancerAdult patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) who have not received prior systemic chemotherapy.MedDRA version: 18.1Level: PTClassification code 10067821Term: Head and neck cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2015-003589-10-FRAstraZeneca AB628
进行中（未招募）
1 期
Study of First Line MEDI4736 with or without Tremelimumab Versus standard ofcare chemotherapy in Recurrent or Metastatic Head and Neck cancerAdult patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) who have not received prior systemic chemotherapy.MedDRA version: 21.1Level: PTClassification code 10067821Term: Head and neck cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2015-003589-10-BEAstraZeneca AB760
进行中（未招募）
1 期
Study of First Line MEDI4736 with or without Tremelimumab Versus standard ofcare chemotherapy in Recurrent or Metastatic Head and Neck cancerAdult patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) who have not received prior systemic chemotherapy.MedDRA version: 21.1Level: PTClassification code 10067821Term: Head and neck cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2015-003589-10-DEAstraZeneca AB760